INT50404

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1993
Last Reported 2010
Negated 0
Speculated 3
Reported most in Abstract
Documents 49
Total Number 55
Disease Relevance 8.61
Pain Relevance 17.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP1A2) oxidoreductase activity (CYP1A2) endoplasmic reticulum (CYP1A2)
enzyme binding (CYP1A2)
Anatomy Link Frequency
1A2 6
liver 4
plasma 3
urine 1
neutrophils 1
CYP1A2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Mexiletine 32 100.00 Very High Very High Very High
lidocaine 31 100.00 Very High Very High Very High
Duloxetine 402 99.88 Very High Very High Very High
sSRI 212 99.72 Very High Very High Very High
cINOD 161 99.72 Very High Very High Very High
Dextromethorphan 3 99.20 Very High Very High Very High
antidepressant 268 99.08 Very High Very High Very High
Potency 23 99.06 Very High Very High Very High
fluoxetine 159 98.92 Very High Very High Very High
Inflammation 71 98.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Urological Neuroanatomy 13 100.00 Very High Very High Very High
Cirrhosis 15 99.44 Very High Very High Very High
INFLAMMATION 90 98.92 Very High Very High Very High
Autoimmune Disease 5 97.66 Very High Very High Very High
Sudden Death 4 95.44 Very High Very High Very High
Critical Illness 9 94.28 High High
Fungal Infection 4 94.00 High High
Overdose 22 93.80 High High
Sprains And Strains 1 91.68 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 17 91.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
Negative_regulation (inhibitor) of cytochrome P4501A2
1) Confidence 0.59 Published 1993 Journal Biochem. Pharmacol. Section Title Doc Link 8466541 Disease Relevance 0 Pain Relevance 0.27
Besides rofecoxib, and possibly mefenamic acid, other NSAIDs were predicted not to significantly inhibit CYP1A2 in human beings.
Negative_regulation (inhibit) of CYP1A2 associated with cinod
2) Confidence 0.59 Published 2008 Journal Basic Clin. Pharmacol. Toxicol. Section Abstract Doc Link 18816299 Disease Relevance 0.07 Pain Relevance 0.29
In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.
Negative_regulation (inhibition) of CYP1A2 associated with inflammation and analgesic
3) Confidence 0.59 Published 2008 Journal Basic Clin. Pharmacol. Toxicol. Section Title Doc Link 18816299 Disease Relevance 0.19 Pain Relevance 0.39
At 100 microM, the other tested NSAIDs and steroids inhibited CYP1A2 less than 35%.
Negative_regulation (inhibited) of CYP1A2 associated with cinod
4) Confidence 0.59 Published 2008 Journal Basic Clin. Pharmacol. Toxicol. Section Abstract Doc Link 18816299 Disease Relevance 0.15 Pain Relevance 0.41
Reversible and irreversible inhibition of by drugs CYP1A2 may provide an explanation for some clinical drug-drug interactions.
Negative_regulation (inhibition) of CYP1A2
5) Confidence 0.59 Published 2009 Journal Curr. Med. Chem. Section Abstract Doc Link 19754423 Disease Relevance 0 Pain Relevance 0.17
In particular, several therapeutic drugs including antofloxacin, carbamazepine, dihydralazine, furafylline, isoniazid, rofecoxib, clorgyline, thiabendazole, and zileuton are mechanism-based inhibitors of CYP1A2.
Negative_regulation (inhibitors) of CYP1A2 associated with carbamazepine
6) Confidence 0.59 Published 2009 Journal Curr. Med. Chem. Section Abstract Doc Link 19754423 Disease Relevance 0 Pain Relevance 0.18
Thus, among the SSRIs, fluvoxamine is the only very potent inhibitor of cytochrome P4501A2 (CYP1A2).
Negative_regulation (inhibitor) of cytochrome P4501A2 associated with ssri
7) Confidence 0.57 Published 1996 Journal Int Clin Psychopharmacol Section Abstract Doc Link 8732441 Disease Relevance 0 Pain Relevance 0.49
Thus, among the SSRIs, fluvoxamine is the only very potent inhibitor of cytochrome P4501A2 (CYP1A2).
Negative_regulation (inhibitor) of CYP1A2 associated with ssri
8) Confidence 0.57 Published 1996 Journal Int Clin Psychopharmacol Section Abstract Doc Link 8732441 Disease Relevance 0 Pain Relevance 0.49
The antidepressant nefazodone and four of its metabolites (meta-chloro-phenylpiperazine, two hydroxylated derivatives, and a triazoledione) were very weak inhibitors of P450-1A2.
Negative_regulation (inhibitors) of P450-1A2 in 1A2 associated with antidepressant
9) Confidence 0.55 Published 1996 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 8986010 Disease Relevance 0 Pain Relevance 0.42
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Negative_regulation (inhibition) of CYP1A2 associated with fluoxetine
10) Confidence 0.55 Published 1996 Journal Eur. J. Clin. Pharmacol. Section Title Doc Link 8880055 Disease Relevance 0 Pain Relevance 0.28
Among them, tanshinone IIA and cryptotanshinone are found to be potent inhibitors to CYP1A2, while artemisinin is a marginal inhibitor to CYP1A2 and glycyrrhetic acid is a weak inhibitor to CYP2C9.
Negative_regulation (inhibitor) of CYP1A2
11) Confidence 0.54 Published 2007 Journal Rapid Commun. Mass Spectrom. Section Abstract Doc Link 17279482 Disease Relevance 0 Pain Relevance 0.21
The potency and specificity of 8-phenyltheophylline as an inhibitor of human hepatic CYP1A2 indicate that the compound may be useful as a chemical inhibitor of this enzyme for further in vitro studies.
Negative_regulation (inhibitor) of CYP1A2 associated with potency
12) Confidence 0.54 Published 2001 Journal Xenobiotica Section Abstract Doc Link 11465391 Disease Relevance 0 Pain Relevance 0.11
Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Negative_regulation (Inhibition) of CYP1A2
13) Confidence 0.54 Published 2001 Journal Xenobiotica Section Title Doc Link 11465391 Disease Relevance 0 Pain Relevance 0.08
Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions.
Negative_regulation (inhibits) of CYP1A2
14) Confidence 0.53 Published 1995 Journal Clin Pharmacokinet Section Abstract Doc Link 8846617 Disease Relevance 0.10 Pain Relevance 0.35
Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9.
Negative_regulation (inhibitor) of CYP1A2
15) Confidence 0.53 Published 2004 Journal Therapie Section Abstract Doc Link 15199661 Disease Relevance 0 Pain Relevance 0.60
Fluvoxamine interacts with these drugs by a mechanism involving inhibition of CYP1A2, CYP3A4, and CYP2C19.
Negative_regulation (inhibition) of CYP1A2
16) Confidence 0.53 Published 1995 Journal Int Clin Psychopharmacol Section Abstract Doc Link 7622807 Disease Relevance 0 Pain Relevance 0.64
Fluvoxamine, as a potent inhibitor of CYP1A2, can inhibit the metabolism of clozapine, resulting in higher plasma concentrations.
Negative_regulation (inhibitor) of CYP1A2 in plasma
17) Confidence 0.52 Published 1997 Journal Clin Pharmacokinet Section Abstract Doc Link 9435993 Disease Relevance 0 Pain Relevance 0.67
Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide.
Negative_regulation (Inhibition) of cytochrome P-450 1A2 in 1A2 associated with mexiletine and lidocaine
18) Confidence 0.51 Published 1999 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 10215663 Disease Relevance 0 Pain Relevance 0.71
No inhibition of CYP1A2, assessed by measuring the conversion of phenacetin to acetaminophen, was noted.
Negative_regulation (inhibition) of CYP1A2 associated with paracetamol
19) Confidence 0.51 Published 1997 Journal Drug Metab. Dispos. Section Abstract Doc Link 9224780 Disease Relevance 0 Pain Relevance 0.22
Selective inhibition of CYP3A4 and CYP1A2 did not reduce, whereas the inhibition of CYP2A6 and CYP2E1 significantly decreased NAPQI formation.
Negative_regulation (inhibition) of CYP1A2
20) Confidence 0.50 Published 2002 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 11866476 Disease Relevance 0.24 Pain Relevance 0.40

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox